Figure 1.

DDX52 expression was overexpressed in MM specimens and predicted poor clinical outcomes in MM patients. (a) Levels of DDX52 expression in MM tissues versus normal samples from a GEO dataset (GSE15605; Normal, n = 16; Tumor, n = 58). (b) OS curve of MM patients based on DDX52 mRNA expression from the GEO dataset (GSE22153 High, n = 25; Low, n = 29). (c) The expression levels of DDX52 in nontumor and tumor tissues were determined by immunohistochemical staining; original magnification 400 × . (d) DDX52 expression scores in tissue nevi and primary and metastatic MM tissues (nevi, n = 18; primary melanoma, n = 62; metastatic melanoma, n = 20). (e) The protein expression level of DDX52 in HaCaT and MM cells was determined by Western blot. ** P < 0.01